Abstract:

Introduction: the problem of restenosis prevention and its early detection is very important in patients who underwent coronary intervention with bare-metal stent (BMS) implantation in acute coronary syndrome (ACS). But when is it necessary to perform elective coronary angiography in order not to miss possible restenosis development? This question needs to be answered.

Aim: was to define the correct period to perform elective coronary angiography after bare-metal stent implantation in acute coronary syndrome.

Material and methods: the study included 124 patients who underwent coronary intervention with BMS implantation in ACS, in period of 1-14 months before current admission. All patients included in this study had indications for repeating coronary angiography and were diagnosed hemodynamically relevant in-stent restenosis. No risk factors of restenosis were revealed at these patients.

Results: average time of restenosis detection was 7,9±1,99 months. Average percent of restenosis among all included patients was 68,6±13,1%. We also revealed direct correlation of percent of restenosis with time of restenosis detection (r=0,5785, p <0,05). Correlation between time and percentage of restenosis and stent type or TIMI grade, was also estimated in this study.

Conclusion: according to results of our study, there are good reasons to repeat coronary angiography in 7-9 month after BMS implantation in ACS, even if patients have no risk factors of restenosis.

References

1.     Bokerija LA, Alekjan BG, Anri M. Rukovodstvo po rentgenojendovaskuljarnoj hirurgii serdca i sosudov. 3-e izd. Tom. 3. Rentgenojendovaskuljarnaja hirurgija ishemicheskoj bolezni serdca [Guide on endovascular surgery of heart and vessels. 3rd ed. Vol. 3. Endovascular surgery of ischemic heart disease]. Moscow: Bakulev Scientific Center of Cardiovascular Surgery. 2008. 648 pages [In Russ].

2.     Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016; 8(10): 1150-1162.

3.     Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017; 39(2): 119-177.

4.     Cortese B, Berti S, Biondi-Zoccai G, et al. Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014; 83(3): 427-35.

5.     Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014; 63(24): 2659-73.

6.     Agostoni P, Valgimigli M, Biondi-Zoccai GG, et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J. 2006; 151(3): 682-9.

7.     Goncharov AI, Kokov LS, Likharev AYu. Otsenka effektivnosti stentirovaniya koronarnyh arterij razlichnymi tipami stentov u bol'nyh IBS. Mezhdunarodnyj zhurnal intervencionnoj kardioangiologii. 2009; 19: 23-24 [In Russ].

Abstract:

Aim: was to estimate the importance of restoring blood flow in vertebral arteries in the segment V1 by stenting in patients with multivessel lesions of extracranial arteries and vertebrobasilar insufficiency (VBI).

Material and methods: study include 59 patients with a dominant, long-existing clinic of vertebrobasilar insufficiency, with multivessel lesions of brachiocephalic arteries, lower brain tolerance to ischemia, with the presence of stenosis of segment V1 of vertebral artery more than 70%, which is regarded by neurologists, as the main reason for VBI. All patients should have been undergone carotid revascularization. However, due to multivessel lesions and low perfusion reserve, all patients as the first stage of treatment - underwent stenting of V1 segment of vertebral artery. In 38 patients bare-metal stent were used, in 14 - drug-eluting stents, in 7 - renal stents. Distal protection was used in 12 patients. In remaining patients - stenting was performed without protection.

Results: in immediate postoperative period, technical, angiographic success and clinical improvement were noticed in 100% of patients. All 59 patients underwent the second and subsequent stages of cerebral revascularization without ischemic episodes. The duration of follow-up was from 6 months to 6 years. After 3 months, 55(93,2%) patients sustained clinical improvement, with no restenosis in stents. 4 patients (6,8%) had no clinical improvement: in one patient after 3 months developed ischemic stroke (IS) in vertebrobasilar system(VBS), due to the occlusion of the stent. 1 patients had stent restenosis with the increase of clinical manifestations of VBI, which required additional stenting. After 14 months, 1 patient after stenting had IS in VBS due to stent fractures caused by bone compression.

Conclusion: stenting of V1 segment of vertebral artery in patients with multivessel lesions of brachiocephalic arteries and clinic of VBI, can be considered as the first stage of cerebral revascularization in case of significant stenosis segment V1 vertebral artery and low tolerance to cerebral ischemia.

References

1.     Savitz S.I., Caplan L.R. Vertebrobasilar disease. N Engl J Med. 2005, 352: 2618-2626.

2.     Caplan L.R., Wityk R.J., Glass T.A., Tapia J., Pazdera L., Chang H.M., Teal P, Dashe J.F., Chaves C.J., Breen J.C., Vemmos K., Amarenco P, Tettenborn B., Leary M., Estol C., Dewitt L.D., Pessin M.S. New England Medical

Center Posterior Circulation registry. Ann Neurol. 2004, 56: 389-398.

3.     Vereshhagin N.V. Patologija vertebral'no-baziljarnoj sistemy i narushenija mozgovogo krovoobrashhenija[Pathology of vertebrobasilar system and cerebral blood flow disorders]. M. 1980; S 28 [In Russ].

4.     Puzin M.N., Zinov'eva G.A., Metelkina L.P. Aspekty medikamentoznogo lechenija bol'nyh s vertebral'no-baziljarnoj nedostatochnost'ju [Aspects of pharmacotherapy in treatment of patients with vertebrobasilar insufficiency]. Klinicheskaja farmakologija i terapija. 2006; 2: 23-26 [In Russ].

5.     Berguer R., Morasch M., Kline R. A review of 100 consecutive reconstructions of the distal vertebraf artery for embolic and hemodynamic disease. J Vasc Surg. 1998, 27 (5): 852-859.

6.     Pokrovskiy A.V., Beloyartsev D.F., Otdalemmie rezultati operatsiy podkluchichno-sonnoi transpozitsii. [Longterm results of operations of the subclavian-carotid transposition.] Angiologia I sosudistaya khirurgia. 2002; 8(2): 84-91.

7.     He Y, Bai W., Li T. et al. Perioperative complications of recanalization and stenting for symptomatic nonacute vertebrobasilar arteryocclusion. Ann Vasc Surg. 2014 Feb; 28 (2): 386-393.

8.     European Stroke Organisation et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011 Nov; 32 (22): 2851-906.

9.     Natsionalnie rekomendacii po vedeniyu patsientov s zabolevaniyami brakhiotsefal’nikh arteriy. [National guidelines on the management of patients with diseases of brachiocephalic arteries.] Angiologia I sosudistaya khirurgia. 2013; 19 (2): attachment 70.

10.   Schonewille W.J., Algra A., Serena J., Molina C.A., Kappelle L.J. Outcome in patients with basilar artery occlusion treated conventionally. J Neurol Neurosurg Psychiatry. 2005, 76:1238-1241.

11.   Coward L.J., McCabe D.J., Ederle J., Featherstone R.L., Clifton A., Brown M.M. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke. 2007, 38: 1526-1530.

12.   Compter A., van der Worp H.B., Schonewille W.J., Vos J.A., Algra .A., Lo T.H., Mali WPThM, Moll FL. and Kappelle L.J. VAST: Vertebral Artery Stenting Trial. Protocol for a randomised safety and feasibility trial. Trials 2008, 9: 65.

13.   Clifton A., Markus H., Kuker W., Rothwell P. E-050. The Rationale for the Vertebral artery Ischaemia Stenting trial (VIST): NeuroIntervent Surg 2013; 5. Suppl 2 A56.

14.   Compter A., et al. VAST investigators. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol. 2015 Jun; 14(6): 606-614.

15.   VIST (Vertebral artery Ischaemia Stenting Trial) ISRCT N 95212240.